Baseline Population Characteristics
| Characteristic | No death (n = 73) | Death (n = 26) | P |
| Age (y) | 66.7 ± 10.5 | 74.0 ± 7.3 | 0.001 |
| Male | 54 (74.0%) | 21 (80.8%) | 0.599 |
| Age at transplantation (y) | 54.3 ± 11.1 | 61.9 ± 6.5 | 0.001 |
| Donor age (y) | 30.2 ± 11.9 | 35.4 ± 10.7 | 0.089 |
| Time after transplantation (y) | 12.5 ± 5.2 | 12.5 ± 5.4 | 0.977 |
| Body mass index (kg/m2) | 26.5 ± 5.6 | 25.8 ± 5.0 | 0.560 |
| Hypertension | 62 (84.9%) | 19 (73.1%) | 0.236 |
| Diabetes | 31 (42.5%) | 15 (57.7%) | 0.252 |
| Dyslipidemia | 53 (72.6%) | 21 (80.8%) | 0.600 |
| Former smoker | 4 (5.5%) | 2 (7.7%) | 0.651 |
| Renal failure | 7 (9.6%) | 4 (15.4%) | 0.472 |
| CAV grade* (0/1/2/3) | 46/17/5/3 | 13/6/2/4 | 0.489 |
| Cytomegalovirus viremia | 10 (13.7%) | 3 (11.5%) | 1.000 |
| History of acute cellular rejection | 10 (13.7%) | 5 (19.2%) | 0.531 |
| History of antibody-mediated rejection | 4 (5.5%) | 4 (15.4%) | 0.154 |
| Medication use | |||
| Aspirin | 39 (53.4%) | 16 (61.5%) | 0.501 |
| β-blockers | 32 (43.8%) | 9 (34.6%) | 0.490 |
| Angiotensin-converting inhibitor or receptor blocker | 36 (49.3%) | 11 (42.3%) | 0.649 |
| Diuretics | 16 (21.9%) | 9 (34.6%) | 0.292 |
| Statins | 58 (79.5%) | 16 (61.5%) | 0.113 |
| Calcineurin inhibitor | 63 (86.3%) | 22 (84.6%) | 1.000 |
| Mammalian target of rapamycin inhibitor | 32 (43.8%) | 9 (34.6%) | 0.490 |
↵* No death (n = 71); death (n = 25).
Data are expressed as number followed by percentage in parentheses or as mean ± SD.